281 related articles for article (PubMed ID: 18487867)
1. [Preclinical data as basis for the design of clinical studies].
Fichtner I
Onkologie; 2008; 31 Suppl 2():34-8. PubMed ID: 18487867
[TBL] [Abstract][Full Text] [Related]
2. [Principle and practice of clinical phase III studies].
Morant R
Onkologie; 2008; 31 Suppl 2():53-7. PubMed ID: 18487870
[TBL] [Abstract][Full Text] [Related]
3. [Principles and practice of clinical phase I studies].
Hanauske AR
Onkologie; 2008; 31 Suppl 2():39-45. PubMed ID: 18487868
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacy standards for clinical trials].
Terkola R
Onkologie; 2008; 31 Suppl 2():25-8. PubMed ID: 18487865
[TBL] [Abstract][Full Text] [Related]
5. [Principles and practice of clinical phase II studies].
Dittrich C
Onkologie; 2008; 31 Suppl 2():46-52. PubMed ID: 18487869
[TBL] [Abstract][Full Text] [Related]
6. [Concepts for clinical testing of biological agents exemplified for vaccines].
Britten CM
Onkologie; 2008; 31 Suppl 2():58-63. PubMed ID: 18487871
[TBL] [Abstract][Full Text] [Related]
7. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
8. [Pharmaceutical aspects of clinical trials: concepts of pharmacokinetic investigations].
Czejka M
Onkologie; 2008; 31 Suppl 2():29-33. PubMed ID: 18487866
[TBL] [Abstract][Full Text] [Related]
9. Improving the evaluation of new cancer treatments: challenges and opportunities.
Rothenberg ML; Carbone DP; Johnson DH
Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
[TBL] [Abstract][Full Text] [Related]
10. [Responsibilities of clinical pharmacology in the early phase of drug development].
Kuhlmann J
Med Klin (Munich); 2000 May; 95(1 Spec No):31-40. PubMed ID: 10851846
[TBL] [Abstract][Full Text] [Related]
11. In vitro methods in human drug biotransformation research: implications for cancer chemotherapy.
Hariparsad N; Sane RS; Strom SC; Desai PB
Toxicol In Vitro; 2006 Mar; 20(2):135-53. PubMed ID: 16359840
[TBL] [Abstract][Full Text] [Related]
12. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
Forster MD; Saijo N; Seymour L; Calvert H
Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
[TBL] [Abstract][Full Text] [Related]
13. Requirements of preclinical examinations.
Lehnert T; Ulbrich B
Lens Eye Toxic Res; 1990; 7(3-4):207-19. PubMed ID: 2100159
[TBL] [Abstract][Full Text] [Related]
14. [Basic rules and problems of phase study of new anticancer agents].
Saito T
Gan To Kagaku Ryoho; 1984 Mar; 11(3):377-82. PubMed ID: 6703716
[TBL] [Abstract][Full Text] [Related]
15. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
Suggitt M; Bibby MC
Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
[TBL] [Abstract][Full Text] [Related]
16. Some thoughts on experimental screening.
Carter SK
Biomedicine; 1975 Jan; 22(1):5-17. PubMed ID: 1101978
[TBL] [Abstract][Full Text] [Related]
17. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
18. Microdialysis: an in vivo approach for measuring drug delivery in oncology.
Brunner M; Müller M
Eur J Clin Pharmacol; 2002 Jul; 58(4):227-34. PubMed ID: 12136367
[TBL] [Abstract][Full Text] [Related]
19. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
Andoh M; Fujiwara Y; Shimada Y
Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
[TBL] [Abstract][Full Text] [Related]
20. New approaches in preclinical and clinical pharmacokinetics.
Graham MA; Kaye SB
Cancer Surv; 1993; 17():27-49. PubMed ID: 8137345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
